Journal of Clinical Microbiology最新文献

{"title":"Multicenter evaluation of the QIAstat-Dx Gastrointestinal Panel 2, a multiplex PCR platform for the diagnosis of acute gastroenteritis.","authors":"Wendy A Szymczak, Anne Line Engsbro, Jan Gorm Lisby, Juan José González-López, Paul Granato, Nathan Ledeboer, Donna M Wolk, Stephen Young, Daniel D Rhoads, Yvan Caspar, Lisa Steed, Romney Humphries, Christopher Bielefeldt, Markus Hermanowski, Juana L de Diego, Hendrik Leibhan, Pau Boher, Carla Camprubí, Maria Orthodoxou, Ester Sala, Sarah Johnson, Martí Juanola-Falgarona, Davide Manissero, Johanna Bialas","doi":"10.1128/jcm.01983-24","DOIUrl":"https://doi.org/10.1128/jcm.01983-24","url":null,"abstract":"<p><p>The QIAstat-Dx Gastrointestinal Panel 2 (GI2 Panel) is a sample-to-answer multiplex PCR instrument that can detect 17 targets in a run time of about 80 minutes. The performance of the QIAstat-Dx GI2 Panel was evaluated by testing 1,939 prospective, 119 prospectively collected and then archived positive clinical samples and 750 retrospective clinical specimens across 13 sites in Europe and the United States. Specimens tested included bulk stool samples preserved in modified Cary-Blair transport medium. For most targets, results were compared to those of the FilmArray GI panel (13/17), and discordant results were adjudicated with a third assay. For the remaining targets (4/17), a composite comparator method was used, which included three comparator assays for each target. Before discordant resolution, the QIAstat-Dx GI2 Panel positive percent agreement (PPA) was 95% or greater for 5/17 targets (<i>Campylobacter</i>, <i>E. coli</i> O157, <i>Cryptosporidium, Cyclospora cayetanensis,</i> and <i>Giardia lamblia</i>) and 90% or greater for 11/17 targets: adenovirus F40/F41, astrovirus, norovirus GI/GII, rotavirus A, <i>Plesiomonas shigelloides</i>, enteropathogenic <i>Escherichia coli</i>, enterotoxigenic <i>E. coli</i>, <i>Salmonella</i>, <i>Yersinia enterocolitica,</i> Shiga-like toxin <i>E. coli</i> (STEC) <i>stx1/stx2</i>, and <i>Shigella</i>/enteroinvasive <i>E. coli</i>. No cases of <i>Entamoeba histolytica</i> were encountered during the clinical study. The negative percent agreement (NPA) was >98.9% for all QIAstat-Dx GI2 Panel targets. The three most common pathogens identified in single and co-infections were enteropathogenic <i>E. coli</i> (9.9%), <i>Campylobacter</i> (5.2%), and norovirus GI/GII (3.1%). In summary, this clinical study examined more than 2,800 samples from Europe and the U.S. using the QIAstat-Dx GI2 Panel and identified 90%-100% PPA and 99% NPA for its 17 targets.IMPORTANCEThe manuscript highlights the significance and impact of the QIAstat-Dx GI2 Panel, a sample-to-answer multiplex PCR instrument capable of detecting 17 targets in approximately 80 minutes. This comprehensive clinical study, conducted across 13 sites in Europe and the United States, evaluated the performance of the panel using over 2,800 clinical samples. The results demonstrate a high accuracy of the QIAstat-Dx GI2 panel, with a PPA equal to or higher than 90% for all targets and an NPA greater than 98.9% for all targets. These findings underscore the reliability and effectiveness of the GI2 panel in the rapid and precise detection of gastrointestinal pathogens, which is crucial for timely diagnosis and treatment of infections.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0198324"},"PeriodicalIF":6.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on North American tick-borne diseases and how to diagnose them.","authors":"Kyle G Rodino, Elitza S Theel, Bobbi S Pritt","doi":"10.1128/jcm.00807-23","DOIUrl":"https://doi.org/10.1128/jcm.00807-23","url":null,"abstract":"<p><p>Recent decades have seen a rise in the incidence of tick-borne diseases in the US, along with an increased number of pathogens transmitted by ticks, and geographic expansion of tick populations. A variety of laboratory testing methodologies are available for the diagnosis of tick-borne diseases, including serology, microscopy, and molecular-based methods. The preferred approach varies by the specific disease, locally available test options, and the stage of illness at patient presentation. This mini-review focuses on updates in our understanding of the epidemiology of tick-borne diseases in the US and advances in the field of laboratory diagnostics.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0080723"},"PeriodicalIF":6.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perfect vs practical: utilizing hematology thin smears for the diagnosis of <i>Plasmodium</i> and <i>Babesia</i>.","authors":"Neil Anderson","doi":"10.1128/jcm.00644-25","DOIUrl":"https://doi.org/10.1128/jcm.00644-25","url":null,"abstract":"<p><p>In the manuscript entitled \"Hematology Thin Smears Perform Equally to Parasitology Thick and Thin Blood Smears for the Diagnosis of <i>Plasmodium</i> and <i>Babesia</i> in a Low-Prevalence Setting,\" the investigators demonstrate that traditional hematology smears (HS) review can have comparable performance to formal blood parasite smears (PS) review. The authors quote a 93.3% sensitivity in comparison to thick smears. This increases to 100% considering only new diagnoses. The implications are that HS can be utilized as a practical and rapid alternative to PS. For clinical laboratories that are limited to only HS capabilities, these findings suggest that they may be able to be less reliant on reference laboratory PS testing, allowing for more rapid diagnosis and management. Even in clinical laboratories that offer both tests, the findings suggest a reassessment of how both HS and PS fit into the diagnostic process for blood parasites. Familiarity with the pros and cons of both approaches allows them to be employed in a way that maximizes patient care impact.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0064425"},"PeriodicalIF":6.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter evaluation of blood culture contamination and blood cultures practices in US acute care hospitals: time for standardization.","authors":"Valeria Fabre, Yea-Jen Hsu, Karen C Carroll, Aaron M Milstone, Alejandra B Salinas, Lilian M Abbo, Chris Bower, Jennifer Berry, Sarah Boyd, Kathleen O Degnan, Pragya Dhaubhadel, Daniel J Diekema, Marci Dress, Baevin Feeser, Mark Fisher, Cynthia Flynn, Bradley A Ford, Erin B Gettler, Laurel J Glasser, Jessica Howard-Anderson, J Kristie Johnson, Sara M Karaba, Justin J Kim, Alyssa Kubischta, Benjamin M Landrum, Marvin Martinez, Amy J Mathers, Leonard Mermel, Rebekah W Moehring, John C O'Horo, Dana E Pepe, S Sonia Qasba, Barry Rittmann, Evan D Robinson, Guillermo Rodríguez-Nava, Rossana Rosa, Jonathan H Ryder, Jorge L Salinas, Aditya Shah, Gregory M Schrank, Mark Shelly, Emily S Spivak, Kathleen O Stewart, Thomas R Talbot, Trevor C Van Schooneveld, Anastasia Wasylyshyn, Avinash Gadala, Zunaira Virk, Sara E Cosgrove","doi":"10.1128/jcm.00530-25","DOIUrl":"https://doi.org/10.1128/jcm.00530-25","url":null,"abstract":"<p><p>Clinical and Laboratory Standards Institute (CLSI) recommends a blood culture contamination (BCC) threshold of <3%, with ≤1% considered optimal. However, there is not a standardized definition of BCC, and the effect of multiple definitions on BCC rates or what definitions laboratories use remain unknown. We surveyed 52 hospitals and analyzed 362,078 blood cultures (BCx) collected 1 September 2019 to 31 August 2021 from 62 intensive care units (ICUs) and 231 wards from 48 of these hospitals. We calculated and compared BCC rates using the College of American Pathologists (CAP) or CLSI criteria (both utilize a limited number of skin commensals to define BCC) and the comprehensive National Healthcare Safety Network (NHSN) commensal list. We characterized factors associated with BCC and related outcomes (central-line associated bloodstream infection [CLABSI] and vancomycin use). BCC, BCx positivity, and single BCx rates were monitored by 100%, 39%, and 21% of hospitals, respectively. Hospitals used CAP (65%), CLSI (17%), and NHSN (17%) criteria to define BCC. Mean BCC rate by CAP (CAP-BCC) was 1.38% for ICUs and 0.96% for wards. BCC rates remained similar by CLSI criteria but increased when using NHSN list. Sharing BCC data outside of the laboratory, measuring additional BCx quality indicators, and limiting central catheter-drawn BCx were associated with lower BCC rates. BCC was associated with higher CLABSI rates in ICUs. This study demonstrated variability in laboratory practices and opportunities to optimize BCx stewardship.IMPORTANCEBlood culture contamination (BCC) is associated with patient harm and unnecessary use of healthcare resources. BCC thresholds have been established; however, multiple BCC definitions exist. There is limited data on how BCC rates differ depending on the BCC definition used, what definitions laboratories most commonly use, or their approach to other blood cultures (BCx) quality indicators such as single rates or BCx positivity. A cross-sectional multicenter survey and analysis of BCx data from intensive care unit and wards revealed that most laboratories did not track single BCx or BCx positivity rates and that there was variability in how BCC was defined. Additionally, BCC rates were influenced by the definition used. BCC was associated with increased central-line associated bloodstream infection rates.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0053025"},"PeriodicalIF":6.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolation and characterization of avian metapneumovirus subtypes A and B associated with the 2024 disease outbreaks among poultry in the USA.","authors":"Jianqiang Zhang, Liying Tian, Jaime Dittman, Baoqing Guo, Kay Kimpston-Burkgren, Erin Kalkwarf, Eman Gadu, Phillip Gauger, Mohamed El-Gazzar, Yuko Sato","doi":"10.1128/jcm.00333-25","DOIUrl":"https://doi.org/10.1128/jcm.00333-25","url":null,"abstract":"<p><p>Avian metapneumovirus (aMPV) is currently classified into four subtypes (aMPV-A, -B, -C, and -D). In late 2023 and early 2024, aMPV-A and aMPV-B were detected in US poultry for the first time, causing significant economic losses. This study analyzed aMPV RT-PCR data from 2,204 samples (1,158 turkey, 936 chicken, and 110 other breeds) submitted to a US veterinary diagnostic laboratory between January and November 2024. A higher percentage of turkey samples (51.04%) tested PCR-positive for aMPV-A and/or aMPV-B compared to chicken samples (15.6%), with aMPV-A showing an overall higher positive rate than aMPV-B, although the positive rates varied by state. Additionally, four aMPV-A and three aMPV-B isolates were successfully recovered from clinical samples using primary chicken embryo lung and/or fibroblast cells. Two aMPV-A isolates (USA/IA55601-6/2024 and USA/IA56509-5/2024) and two aMPV-B isolates (USA/NC20487-GA/2024 and USA/NC23734-GA/2024) were adapted to grow efficiently in a Vero cell line, reaching titers of ~10⁴-10⁶ TCID₅₀/mL between passages 4 and 10 for aMPV-A and between passages 1 and 10 for aMPV-B. Whole genome sequencing of the two aMPV-A and two aMPV-B isolates at different passages revealed that the viruses progressively acquired several nucleotide changes, some of which led to amino acid substitutions in different viral proteins during 10 passages in cell culture. Comparative analysis with 46 aMPV-A, -B, -C, and -D GenBank sequences showed that US aMPV-A and aMPV-B strains were genetically closely related within their subtypes. These cell culture-adapted US aMPV-A and aMPV-B isolates provide valuable tools for further characterization of aMPV and vaccine development.</p><p><strong>Importance: </strong>Avian metapneumovirus (aMPV) subtypes A and B were first detected in US poultry in late 2023 and early 2024, rapidly spreading nationwide and posing a significant threat to the industry. This study analyzed RT-PCR data from 2,204 clinical samples (January to November 2024) to determine aMPV-A and aMPV-B detection rates across poultry species, age groups, and states, providing insights into their epidemiology in the USA. Modified live vaccines are urgently needed to control aMPV but are hindered by the lack of US isolates growing efficiently in cell culture. We successfully isolated aMPV-A and aMPV-B in primary chicken embryo cells and adapted them to a Vero cell line. Their infectious titers and genetic stability were characterized over serial passages. These US aMPV-A and aMPV-B cell culture isolates provide valuable tools for studying pathogenesis, determining virus infectious doses, evaluating disinfectants and antivirals, and developing vaccines.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0033325"},"PeriodicalIF":6.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of plasma cell-free DNA PCR for non-invasive diagnosis of mucormycosis.","authors":"Jordan Mah, Anthony Lieu, Veronica Nicholas, Angel Moreno, Kanagavel Murugesan, Indre Budvytiene, Niaz Banaei","doi":"10.1128/jcm.00796-25","DOIUrl":"https://doi.org/10.1128/jcm.00796-25","url":null,"abstract":"<p><p>Diagnosis of mucormycosis poses a substantial challenge due to the lack of a non-invasive biomarker and limitations of conventional diagnostics using invasive specimens. The aim of this study was to characterize the performance of Mucorales plasma cell-free DNA (cfDNA) PCR in immunosuppressed and non-immunosuppressed patients with pulmonary, disseminated, and localized mucormycosis. Patients with Mucorales plasma cfDNA test results were retrospectively categorized as proven or probable for sensitivity analysis and as no Mucorales infection for specificity analysis. In total, 85 positive and 212 negative Mucorales plasma cfDNA test results in unique patients were included in this study. Per the expert definitions, 47 patients had proven or probable mucormycosis, and 171 did not have invasive Mucorales infection. The Mucorales plasma cfDNA PCR had an overall sensitivity and specificity of 85.1% (40/47, 95% CI, 71.7-93.8) and 92.9% (158/170, 95% CI, 88.0-96.3), respectively. The sensitivity was 92.1% (35/38, 95% CI, 78.6-98.3) and 55.6% (5/9, 95% CI, 21.2-86.3) in patients with and without immunosuppression, respectively, and 100% (14/14, 95% CI, 76.8-100), 89.5% (17/19, 95% CI, 66.9-98.7), and 64.3% (9/14, 95% CI, 35.1-87.2) in patients with disseminated, pulmonary, and localized mucormycosis, respectively. Mucorales plasma cfDNA PCR is a sensitive and specific non-invasive testing modality for the diagnosis of mucormycosis in immunosuppressed patients and those with pulmonary and disseminated infection.IMPORTANCEMucormycosis is an invasive mold infection associated with high morbidity and mortality. Early diagnosis and effective antifungal treatment are critical for improving clinical outcomes. However, diagnosis of mucormycosis is often delayed due to the lack of a non-invasive biomarker and insensitivity of culture and non-specificity of histopathology performed on invasive specimens. Mucorales plasma cell-free DNA (cfDNA) PCR is a novel testing modality that allows non-invasive diagnosis of mucormycosis. In the current study, we evaluated the clinical performance of a pre-analytically optimized Mucorales plasma cfDNA PCR in immunosuppressed and non-immunosuppressed patients with pulmonary, disseminated, and localized infections. We show that Mucorales plasma cfDNA PCR is highly sensitive and specific in immunosuppressed patients with pulmonary and disseminated infections. Thus, the Mucorales plasma cfDNA PCR represents an accurate diagnostic tool for non-invasive diagnosis of mucormycosis, which may enable early treatment and improved outcomes in immunosuppressed patients with mucormycosis.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0079625"},"PeriodicalIF":6.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of the LIAISON PLEX yeast blood culture assay for identifying 16 invasive fungal pathogens in blood cultures.","authors":"Christopher L Emery, Neelam Dhiman, Siu-Kei Chow, Gwyn Peterson, Paul Granato, Brian Bernier, Janet Farhang","doi":"10.1128/jcm.00362-25","DOIUrl":"10.1128/jcm.00362-25","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Fungi frequently cause potentially life-threatening bloodstream infections, particularly in immunocompromised and hospitalized individuals. Molecular methods can allow earlier pathogen identification for faster optimization of appropriate therapy. This multisite study evaluated the analytical and clinical performance of the automated multiplex LIAISON PLEX Yeast Blood Culture nucleic acid assay (Luminex Corporation, Northbrook, IL), which detects and identifies 14 &lt;i&gt;Candida&lt;/i&gt; and 2 &lt;i&gt;Cryptococcus&lt;/i&gt; pathogens from positive blood cultures. Samples included 69 prospectively collected specimens, 63 pre-selected samples, and 829 contrived specimens. The assay demonstrated 100% positivity in detecting target fungal pathogens and 0% positivity in negative blood cultures. All 13 tested bottle/matrix types gave 100% detection of six evaluated pathogens. Limits of detection ranged from 7.77 × 10&lt;sup&gt;2&lt;/sup&gt; CFU/mL (&lt;i&gt;Candida famata&lt;/i&gt;) to 2.83 × 10&lt;sup&gt;5&lt;/sup&gt; CFU/mL (&lt;i&gt;Candida albicans&lt;/i&gt;). The assay identified five strains tested for each of the 16 target species, indicating good inclusivity. No cross-reactivity occurred with 40 bacterial strains. Cross-reactivity with 2 of 37 off-target fungi (&lt;i&gt;Candida&lt;/i&gt; [&lt;i&gt;Yarrowia&lt;/i&gt;] &lt;i&gt;deformans&lt;/i&gt; and &lt;i&gt;Candida pseudohaemulonii&lt;/i&gt;) was predicted by &lt;i&gt;in silico&lt;/i&gt; sequence analyses. Low concentrations of on-panel fungi were detectable alongside high concentrations of potential fungal and bacterial confounders. Reproducibility was 100% within-lab and 99.7% across sites. For combined prospective plus pre-selected specimens, sensitivity/positive percent agreement (PPA) was 100% for detected fungal pathogens, and specificity/negative percent agreement (NPA) was 97.6%‒100.0%. Common pathogens in prospective samples were &lt;i&gt;Candida glabrata&lt;/i&gt; (36%) and &lt;i&gt;C. albicans&lt;/i&gt; (25%). Contrived specimen PPA was 100%, and NPA was ≥99.6%. The LIAISON PLEX Yeast Blood Culture assay provides outstanding sensitivity and specificity for rapidly identifying and differentiating fungal pathogens in positive blood culture specimens.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Bloodstream fungal infections have serious risks of illness and death. Optimal treatment requires early pathogen identification so appropriate antifungal therapy can be immediately started. Blood culture is standard for confirming fungal infection but takes several days for results and may not provide detailed pathogen information. The LIAISON PLEX Yeast Blood Culture assay quickly analyzes fungus-positive blood cultures to identify 16 pathogenic fungi, including multiple &lt;i&gt;Candida&lt;/i&gt; spp. that are common causes of bloodstream infection. This study demonstrated a high degree of test accuracy and reliability in rapidly identifying the infective pathogen in blood cultures from 132 patients with demonstrated culture-positive fungal infections. Assay performance was confirmed in 829 contrived samples, whereby samples were spiked with different funga","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0036225"},"PeriodicalIF":6.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The <i>Staphylococcus aureus</i> complex: implications for the clinical microbiology laboratory.","authors":"Austin Yan, Julianne V Kus, Nadia Sant","doi":"10.1128/jcm.01276-24","DOIUrl":"10.1128/jcm.01276-24","url":null,"abstract":"<p><p>In the last 15 years, advances in diagnostic microbiology have enabled more detailed characterization of human bacterial pathogens. These changes have led to the description of new species within the <i>Staphylococcus aureus</i> complex, including <i>S. aureus</i> subspecies <i>anaerobius</i>, <i>Staphylococcus argenteus</i>, and <i>Staphylococcus schweitzeri</i>. In this minireview, we discuss the history, epidemiology, microbiology, genomics, and clinical significance of the <i>S. aureus</i> complex and provide a guide for laboratories to reliably detect and differentiate these novel species.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0127624"},"PeriodicalIF":6.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-fungal pathogens detected by broad-range fungal polymerase chain reaction.","authors":"Sonya Ahuja, Joshua A Lieberman","doi":"10.1128/jcm.00087-25","DOIUrl":"10.1128/jcm.00087-25","url":null,"abstract":"","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0008725"},"PeriodicalIF":6.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance evaluation of a commercial multiplex pathogen panel for the diagnosis of pediatric joint infections.","authors":"Lawson Copley, Gina Lee, Mary Villani, Naureen Tareen, Laura M Filkins","doi":"10.1128/jcm.00278-25","DOIUrl":"10.1128/jcm.00278-25","url":null,"abstract":"<p><p>This study evaluates the performance of the BIOFIRE Joint Infection (JI) Panel compared to joint fluid culture and/or 16S rRNA PCR, followed by Sanger sequencing (16S PCR/S) for the diagnosis of joint infections in pediatric patients. An on-panel organism was detected by standard-of-care joint (SOCj) studies (joint fluid culture with or without 16S PCR/S, as ordered by the treating physician) in 29/65 samples (44.6%), and the same organism was detected by the BIOFIRE JI panel in all samples. The cumulative positive percent agreement in the detection of on-panel genus or species-level targets by the BIOFIRE JI panel was 100% (36/36), 100% (25/25), and 100% (27/27), and the negative percent agreement was 99.7% (1,974/1,979), 99.2% (1,974/1,990), and 99.7% (1,303/1,307) compared to detection by SOCj, joint fluid culture only, or 16S PCR/S only, respectively. The potential clinical impact of employing the BIOFIRE JI panel was predicted by retrospective adjudication using a study-specific rubric. We predicted that 27.7% (18/65) of BIOFIRE JI panel results could have had a positive impact on patient care. One case (1.5%) was predicted to potentially have a negative impact, and three cases (4.6%) were adjudicated to have an unknown impact. All organisms detected by 16S PCR/S, but not by culture, were also detected by the BIOFIRE JI panel during this study.</p><p><strong>Importance: </strong>The BIOFIRE JI Panel has been limitedly evaluated in pediatric patients. Our study shows a strong agreement between the BIOFIRE JI panel and culture and/or 16S rRNA PCR with Sanger sequencing for the detection of the most common pathogenic causes of joint infection in children. The faster time to results of the BIOFIRE JI panel has the potential to guide optimal treatment faster than conventional methods.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0027825"},"PeriodicalIF":6.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}